Article Text

Download PDFPDF
Brimonidine gel and adverse cardiovascular effects

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A safety update on brimonidine gel (Mirvaso) has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA).1 Brimonidine, an alpha2 adrenergic receptor agonist, is available as a topical gel indicated for the symptomatic treatment of facial erythema of rosacea in adults.2 The MHRA statement warns against using the product on damaged or irritated skin, including after laser therapy. This follows reports of systemic cardiovascular effects …

View Full Text